Evolutionary Dynamics of Brain, Lung, and Hematopoietic Tumors

描述（由申请人提供）：PS-OC组织了一个领导结构，提供专业知识，并充分支持所有举措。领导层由主要研究者Franziska Michor博士和高级合作研究者Eric Holland博士组成。支持人员包括管理员/教育主任，沙漠马赠款，研究/项目经理，Raquel Sanchez，MBA和生物统计学家，Mithat Gonen，博士。PS-OC的领导和支持人员，也称为行政部门，将共同努力，支持和完成拟议的研究项目，核心，教育和培训股，外展和传播股，以及试点和跨网络项目。PS-OC指导委员会（PSC）将每年举行一次会议，由每个PS-OC的两名调查员组成。主要研究者Franziska Michor博士和高级合作研究者Holland博士将代表我们的PS-OC参加PSC。中心咨询委员会（CAC）将汇集具有物理科学和基础科学专业知识的研究人员，组成一个由投票和非投票成员组成的小组。具体而言，CAC将由以下投票成员组成：两名物理科学成员，Franziska Michor（PD/主要研究者），博士和Chris Sander，博士;两名生物学/临床成员，William Pao，MD/PhD和Eric Holland，MD/PhD;以及一名NCI指定的投票成员。非投票成员将包括至少两名具有广泛专业知识的外部顾问，其中一名外部顾问将在信号转导，癌症生物学，项目管理方面具有广泛的熟练程度，并专注于与PS-OC项目无关的肿瘤类型。至少有一名其他外部顾问将具有以下一项或多项的先进知识：进化理论，非进化癌症系统，发育生物学，脑癌，肺癌，白血病，应用数学或工程/微制造。

DESCRIPTION (provided by applicant): The PS-OC has organized a leadership structure to provide expertise and fully support all initiatives. The leadership consists of the Principal Investigator, Franziska Michor, PhD, and the Senior Co-investigator, Eric Holland, MD, PhD. Support personnel consists of the Administrator/Education Director, Desert Horse-Grant, Research/Project Manager, Raquel Sanchez, MBA, and Biostatistician, Mithat Gonen, PhD. The PS-OC leadership and support personnel, also known as the Administration, will work collectively to support and accomplish the proposed research projects, core, educational and training unit, outreach and dissemination unit, and pilot and trans-network projects. The PS-OC Steering Committee (PSC) will meet annually and will consist of two investigators from each PS-OC. The Principal Investigator, Dr. Franziska Michor, and the Senior Co-investigator, Dr. Holland, will represent our PS-OC at the PSC. The Center Advisory Committee (CAC) will bring together investigators with expertise in both the physical sciences and the basic sciences to form a group of voting and non-voting members. Specifically, the CAC will be made up of the following voting members: two physical sciences members, Franziska Michor (PD/Principal Investigator), PhD, and Chris Sander, PhD; two biological/clinical members, William Pao, MD/PhD, and Eric Holland, MD/PhD; and an NCI appointed voting member. Non-voting members will include at least two external advisors with a wide spectrum of expertise, One external advisor will have a broad proficiency in signal transduction, cancer biology, program management and a focus on a tumor type unaffiliated with the projects of the PS-OC. At least one other external advisor will have advanced knowledge of one or more of the following: evolutionary theory, non-evolutionary cancer systems, developmental biology, brain cancer, lung cancer, leukemia, applied mathematics or engineering/micro fabrication.